Articles On Adalta (ASX:1AD)
Title | Source | Codes | Date |
---|---|---|---|
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX Paradigm Biopharmaceuticals rose 151% in Novembe... |
Stockhead | 1AD | 8 hours ago |
WTF with 1AD: New approach to treating fibrosis with lead i-body drug candidate
What is idiopathic pulmonary fibrosis (IPF)? What’s it like living with it? And what treatments are currently available? AdAlta (ASX:1AD) managing director and CEO Dr Tim Oldham joins the Stockhead TV studio to investigate these questions a... |
Stockhead | 1AD | 1 week ago |
Closing Bell: Uranium stocks jump on Russia news; Resolute pays $160m to settle Mali dispute
ASX up as mining gains offset tech and bank losses Silex, Paladin and uranium stocks soar on supply squeeze Goldman cuts Aussie GDP forecast as US tariffs loom After a soft start to the day, the ASX bounced back and closed the day 0.3% ... |
Stockhead | 1AD | 2 weeks ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | 1AD | 4 weeks ago |
AdAlta secures top talent to lead AdCella and AdSolis as boost in clinical activity looms
AdAlta boosts leadership of subsidiaries with appointments of two consultant chief medical officers AdCella’s Kevin Lynch will support selection of in-licensed cellular immunotherapies and the design and execution of Phase 1 clinical trial... |
Stockhead | 1AD | 1 month ago |
Closing Bell: WiseTech drags again; 29Metals sinks 20pc on copper output
ASX edges slightly up by 0.12pc as traders rethink rate cuts Consumer staples shine while gold miners gain amid global tensions 29Metals plunges after cash reserve drop and production decline The ASX ticked up higher by 0.1% on Wednesd... |
Stockhead | 1AD | 1 month ago |
Tony’s Takeaway: A second helping of biotech picks
Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto... |
Stockhead | 1AD | 1 month ago |
Long Shortz with AdAlta: Global health experts recruited for idiopathic pulmonary fibrosis drug
Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. The company’s formed a clinical advisory board to support the development of... |
Stockhead | 1AD | 1 month ago |
Break it Down: AdAlta moves into a higher realm of drug development with new advisory board
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on AdAlta (ASX:1AD) recruiting a team of world leaders in idiopathic pulmonary fibrosis to form a company cli... |
Stockhead | 1AD | 1 month ago |
AdAlta forms clinical advisory board to advance IPF drug candidate
AdAlta forms a clinical advisory board to advance its lead i-body enabled drug candidate AD-214 Board members are renowned experts in pulmonary medicine and fibrosis AdAlta has also engaged a specialist adviser for Idiopathic Pulmonary Fib... |
Stockhead | 1AD | 1 month ago |
Closing Bell: Energy stocks cushion ASX’s mini crash; Infinity soars on Cangai copper acquisition
ASX 200 index falls despite gains in energy stocks Smaller oil and gas firms benefit from rising crude prices Iron ore stocks drop as prices retreat The ASX 200 index fell hard on Friday, down by 0.75%, despite some gains in the Ener... |
Stockhead | 1AD | 1 month ago |
Stocks of the Hour: Platina Resources, Solstice Minerals, AdAlta
To register for today's webinar click here. Platina Resources Limited (ASX:PGM) has confirmed two gold intersections at its Challa Gold Project in Western Australia, including 12m at 0.66g/t Au from aircore hole CHAC0155. The findings sug... |
ShareCafe | 1AD | 2 months ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | 1AD | 2 months ago |
Up 19% in 2024, is it time to buy or sell Coles shares?
Coles Group Ltd (ASX: COL) shares have enjoyed a strong run in 2024. They are up 18.7% this year to date and finished trading on Tuesday at $19.12 apiece. With the S&P/ASX 200 Index (ASX: XJO) 7.2% higher in the same period, Coles sh... |
Motley Fool | 1AD | 2 months ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | 1AD | 3 months ago |
Closing Bell: ASX up 0.22pc after slow start; iron ore miners, REA weigh on market
The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness After a sluggish start, the ASX ended Monday higher by 0.22% as September trading... |
Stockhead | 1AD | 3 months ago |
ASX Market Update: Early Slump and Key Company Movements
Local markets opened lower this morning, with the decline slightly exceeding expectations. Despite a decent performance on Wall Street overnight, which might have suggested a more positive start for the ASX, the Australian share market face... |
Kalkine Media | 1AD | 3 months ago |
Health Kick Podcast: Creating hope for debilitating diseases
Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Tim Oldham, CEO and managing director at AdAlta (ASX:1AD). The biotech company is devo... |
Stockhead | 1AD | 3 months ago |
AdAlta (ASX:1AD) – Webinar Presentation
Tim Oldham – CEO & Managing Director – AdAlta Limited (ASX:1AD) is a clinical-stage biotechnology company. The company’s lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis. |
ShareCafe | 1AD | 3 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | 1AD | 3 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | 1AD | 4 months ago |
Closing Bell: Local tech talent steps up ahead of blockbuster inflation week
ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners The local benchmark moved strongly into positive terri... |
Stockhead | 1AD | 4 months ago |
AdAlta boosts balance sheet, makes key advances in Q4 FY24
AdAlta entered collaboration with SYNthesis BioVentures Fund to establish AdCella during Q4 FY24 Cell Therapies chosen as preferred manufacturing partner for AdCella’s cellular immunotherapies Institutional investment, reduced expenditure... |
Stockhead | 1AD | 4 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | 1AD | 5 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | 1AD | 6 months ago |
Closing Bell: ASX gains as house prices keep climbing; cash is dead as Armaguard falters
ASX starts June positively, extending May gains Property prices in Australia rose by 0.8% in May, with Sydney remaining the most expensive city Lovisa plunges by -10% as John Cheston takes over as CEO The ASX has started the month of... |
Stockhead | 1AD | 6 months ago |
AdAlta secures $1.9m from exercise of options to advance critical discovery programs
1AD raises $1.9 million of new equity from the exercise of listed 1ADOA options, led by an existing major shareholder Options exercised at a 20% premium to the closing price on May 29 2024 Proceeds from exercised options to help AdAlta adv... |
Stockhead | 1AD | 6 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | 1AD | 6 months ago |
Long Shortz with AdAlta: Progressive partnership to spread life-saving immunotherapies
Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. The Aussie biotech has chosen Cell Therapies as its preferred manufacturer fo... |
Stockhead | 1AD | 6 months ago |
AdAlta appoints Melbourne-based Cell Therapies as preferred manufacturing partner
AdAlta (ASX:1AD) has announced an agreement under which Cell Therapies will be established as the preferred manufacturing partner of its cellular immunotherapies. |
BiotechDispatch | 1AD | 6 months ago |
Closing Bell: Oil weighs on flat ASX; Errawarra jumps 65pc on scent of fresh lithium
ASX flat on Monday, ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower Chinese shares slump on new US tariffs After advancing 1.5% last week, the ASX200 fell flat on Monday – greenish by 0.01% – dragged down m... |
Stockhead | 1AD | 6 months ago |
ASX Health Stocks: Optiscan jumps after signing robotic surgery deal with Mayo Clinic
Optiscan signs deal with world-renowned Mayo Clinic AdAlta designates Cell Therapies as its manufacturing partner Ecofibre jumps after entering sell and leaseback agreement in US Optiscan signs deal with Mayo Clinic Optiscan Imaging (AS... |
Stockhead | 1AD | 6 months ago |
Market Highlights: Novovax doubles; Chalmers calls critical minerals a ‘golden opportunity’
ASX to open higher as the S&P 500 inches toward a new high Tesla to spend US$500m in in expanding its charging network Treasurer Jim Chalmers calls critical minerals a “golden opportunity” Aussie shares are poised to open lower o... |
Stockhead | 1AD | 6 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | 1AD | 7 months ago |
Closing Bell: ASX finds some bulldog as copper-gold pup Canterbury pops, just like we said it would
The ASX belts one out on Monday, up 0.8pc All 11 sectors are better for it Canterbury Resources grows by half The benchmark Aussie index has started the week with decisive and broad based gains. All 11 sectors ended Monday higher. US Fu... |
Stockhead | 1AD | 7 months ago |
AdAlta locks in $3.7m to speed up Phase II clinical trials, near-term partnerships
AdAlta has received an institutional investment of up to $3m from New Life Sciences LLC and $700,000 from Meurs Group The two investments will allow the company to accelerate the recent SYNBV MoU An extended final repayment has also been s... |
Stockhead | 1AD | 7 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | 1AD | 7 months ago |
Long Shortz with AdAlta: Strengthening bonds in the fight against cancer
Stockhead’s Ashtyn Hiron sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news. AdAlta announced a partnership with venture capital firm SYNthesis BioVentur... |
Stockhead | 1AD | 7 months ago |
AdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapy
Special Report: AdAlta and SYNthesis BioVentures Fund (SYNBV) are collaborating to form AdCella, a jointly owned entity aimed at facilitating the entry of innovative cellular immunotherapies from Asia into western regulated markets, leverag... |
Stockhead | 1AD | 7 months ago |
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1
It’s been a tough couple of years for ASX health care with challenging economic conditions including steep interest rates rises to combat soaring inflation hitting the sector like a nasty dose of influenza. Furthermore, a frenzy around the... |
Stockhead | 1AD | 8 months ago |
AdAlta (ASX:1AD) – Webinar Presentation
Tim Oldham – CEO & Managing Director – AdAlta (ASX:1AD) is a clinical-stage biotechnology company using its i-body platform to discover and develop next-generation protein therapeutics addressing drug targets that are challenging for... |
ShareCafe | 1AD | 8 months ago |
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results
ASX health sector rises in line with broader markets in the past five days AdAlta reports positive Phase 1 extension trial results of AD-214 into IPF Mach7 signs $3.1 million, three-year renewal contract with Penn State Health Morgans h... |
Stockhead | 1AD | 8 months ago |
AdAlta announces positive results from Phase 1 extension study of lead asset AD-214
AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis. |
BiotechDispatch | 1AD | 8 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | 1AD | 8 months ago |
Closing Bell: Cettire rejects AFR claims, GDP’s gone back to the 90’s and ASX200 ends above the ice
Local markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1 The ASX 200 traded sideways again today, closing the day +0.1% higher as gains in Financials and Real Estate were offset by losses in Tech and Mining stocks.... |
Stockhead | 1AD | 8 months ago |
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical studies and partnering
Phase I extension study of AD-214 tested the target Phase II dose of AD-214 in healthy volunteers AdAlta says the findings positively answer key partner questions and support progressing AD-214 Phase II clinical studies in Idiopathic Pulmo... |
Stockhead | 1AD | 8 months ago |
AdAlta’s AD-214 demonstrates safety and efficacy potential for fibrotic disease treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studi... |
smallcapsau.mystagingwebsite.com | 1AD | 8 months ago |
Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
06 Mar 2024 - A snapshot of the stocks on the move, featuring Atomo Diagnostics (ASX:AT1), AdAlta (ASX:1AD) and Aruma Resources (ASX:AAJ). |
FNN | 1AD | 8 months ago |
Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
To register for Friday's webinar click here. Atomo Diagnostics (ASX:AT1) has announced securing purchase orders from Viatris Healthcare Pty Ltd for approximately AUD $970,000 worth of HIV Self-Tests, manufactured by Atomo under the Mylan... |
ShareCafe | 1AD | 8 months ago |
ASX Health Stocks: Atomo pops 90pc after purchase order; AdAlta up 20pc on Phase 1 results
Atomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key results from Phase 1 study Race Oncology’s drug shows potent anticancer activity Atomo up 90pc on HIV kit sales Atomo Diagnostics (ASX:AT1)... |
Stockhead | 1AD | 8 months ago |